Javier Fernández Díaz

Javier Fernández Díaz has a strong background in biomedical and evolutionary biotechnology, with a focus on cancer research. Javier began their career as a Trainee at Palma Aquarium in 2014 before moving on to the Cellular and Molecular Biomedicine Laboratory at the Universitat de les Illes Balears, where they conducted research for their Bachelor's thesis on the effects of lipid compounds on prostatic cancer cells. Their findings led to the selection of a compound for in vivo studies in mice and showed promising results in decreasing tumor size.

In 2014, Javier also completed their Master's thesis at the same institution, investigating the effects of lipid compounds on pancreatic cancer cells. This research involved designing lipid compounds through rational design and evaluating their impact on the Mia-PaCa-2 cell line.

Javier's academic achievements continued with their PhD on "Biomedical and Evolutionary Biotechnology" at Laminar Pharma, which they started in 2015 and defended successfully in 2021. Their thesis focused on developing glucosylceramide synthase inhibitors as a therapeutic target for glioma and other types of cancer. The research involved various cancer cell biology experiments, including animal models and xenograft tumors, as well as molecular biology and drug design. Javier's PhD was awarded the highest grade (CUM LAUDE) and received an international mention, recognizing their contribution to the field.

Currently, Javier holds the position of Business Development Manager / CSO Associate at Laminar Pharma, starting in 2023.

Javier Fernández Díaz pursued their education at the Universitat de les Illes Balears. From 2010 to 2014, they obtained a Bachelor's Degree in Biología celular y molecular, achieving a grade of 7,00. Javier continued their studies at the same university, earning a Master's Degree in Biotechnology from 2014 to 2015, with a notable grade of 9.1.

In addition to their academic achievements, Javier gained several certifications. In September 2011, they obtained a European B1 driving license. Javier also acquired an APTIS level C certification from the British Council in September 2014. Lastly, in October 2015, they received Category B on animal experimentation certification from Animalia.